The recognized leader in clinical trials resulting in new and better medicines.

July 10, 2020 – Update on COVID-19 (“Coronavirus”)
To: Our Sponsors, CROs, Patients, and Employees:

Over the past several months, CenExel and its Centers of Excellence have embraced change in the face of COVID-19, implementing new protocols and procedures to ensure the safety of our staff and patients.

We enhanced screening for everyone entering our facilities before they gain admittance into our office or clinic areas. We established a COVID-19 Task Force to ensure consistent implementation of our policies and procedures and reinforce internal communication. We provided additional personnel for cleaning and disinfecting as well as additional materials to our staff. We cross-trained and prepared for a variety of contingency plans. We will continue to monitor the local situation at each of our Centers, coordinate with the proper authorities, and update our policies and procedures as needed to ensure safety.

Because we conduct essential clinical research healthcare services, we have continued operations throughout the global pandemic. We are excited to report the vast majority of delayed trials have restarted. Across our five CenExel Centers of Excellence since March 1, we have screened more than 700 patients and enrolled more than 400 into our ongoing studies. We have been able to meet and exceed our enrollment targets in a safe and effective manner. Our goal is to ensure reliable clinical trial results while keeping the safety of patients and employees as our main priority.

Please contact us for any additional information regarding our COVID-19 response.